The vagina is not merely an anatomical passageway but a finely tuned microbial ecosystem, and according to a new review published in Biology of Sex Differences, that ecosystem may be playing an underappreciated role in one of the most alarming trends in modern medicine: the rise of drug-resistant sexually transmitted infections. The paper, authored by Samantha J. Webster of Griffith University and colleagues, argues that the social contexts in which people live, love and access healthcare are inseparable from the microbial ecology of the vaginal microbiome, and that together these forces may be creating ideal conditions for antimicrobial-resistant STIs, known as AMR-STIs, to acquire, evolve and spread.
At the heart of the review is a deceptively simple proposition: sexually transmitted infections do not emerge in a biological vacuum. The vaginal microbiome, or VMB, is a complex community of microorganisms whose composition varies dramatically from person to person. In many individuals, the ecosystem is dominated by Lactobacillus species, particularly Lactobacillus crispatus, which maintain a low-pH environment hostile to pathogens. In others, the community shifts toward Lactobacillus iners or toward diverse assemblages of anaerobic bacteria such as Gardnerella vaginalis. These shifts are not random. They fluctuate with hormonal milestones, menstrual cycles, sexual behaviour, race, ethnicity, body mass index, stress and a host of other factors, many of which lie outside an individual’s personal control.
The authors emphasize that this variability matters clinically. Different VMB compositions appear to influence susceptibility to STI acquisition and transmission, yet the precise relationships between microbial composition, the vaginal microenvironment and infection outcomes remain poorly characterized, particularly for women and gender-diverse people. Vaginal STI infections are also less likely to produce noticeable symptoms than infections in other anatomical sites, which means that women and gender-diverse individuals have often been overlooked as potential reservoirs of STIs within broader sexual networks. This gap in surveillance and understanding, the authors contend, is not merely an academic oversight but a public health vulnerability.
The review arrives at a moment of genuine urgency for sexual health policy. In Australia, doxycycline post-exposure prophylaxis, or Doxy-PEP, has recently become available to gay and bisexual men who have sex with men, a population in which AMR-STIs such as resistant Neisseria gonorrhoeae are highly prevalent. The intervention involves taking the antibiotic doxycycline proactively after sex to prevent infection, and early evidence suggests it can reduce STI acquisition in the groups studied. But the Australian guidelines exclude people assigned female at birth and fail to specify how the intervention should be applied to gender-diverse individuals. That exclusion creates a striking asymmetry: one segment of a sexual network receives prophylactic antibiotics while their partners do not, a situation the authors argue demands rigorous investigation of downstream effects.
From a microbiological standpoint, the concern is well grounded. Antimicrobial resistance does not simply appear; it is selected for. The review describes the vaginal microenvironment as, hypothetically, a near-perfect platform for the development and emergence of AMR-STIs. Bacteria within the VMB can form biofilms, structured communities encased in extracellular polymeric substances that function as a kind of biological glue. Biofilms concentrate microorganisms in close physical proximity, creating abundant opportunities for horizontal gene transfer, the process by which microbes exchange genetic material, including antimicrobial resistance genes. A pathogen such as N. gonorrhoeae, encountering a vaginal biofilm rich in resistant commensal organisms, could in principle acquire resistance genes that would otherwise remain sequestered in harmless residents.
The authors also point to the delicate balance that defines VMB health. The ecosystem exists in a continuous negotiation between protective Lactobacillus dominance and opportunistic pathogens poised to exploit any disturbance. Antibiotic exposure is precisely such a disturbance. When antibiotics are deployed prophylactically in one part of a sexual network, the microbiomes of untreated partners may nonetheless experience ecological knock-on effects through repeated exposure to resistant organisms, altered transmission dynamics and the selective pressures created by partners’ antibiotic use. The review stresses that antimicrobial treatments applied to specific population groups can themselves act as selective pressures for AMR-STIs and require pragmatic study that accounts for these downstream consequences.
What distinguishes this review from much of the existing literature is its insistence on the social dimension of microbial ecology. Sex, gender and sexuality, the authors write, are inextricably linked and highly relevant to STIs, and global patterns of sexual and reproductive health correlate strongly with the socioeconomic status of a country or community. Sexual networks are not abstract mathematical constructs; they are shaped by identity, behaviour, stigma and access to care. The review highlights how race and ethnicity influence VMB composition, how lifestyle factors and menstrual milestones reshape the microbial balance over time, and how systematic historical neglect has left women and sexuality and gender diverse minorities with gaps in both scientific understanding and medical treatment options.
The authors extend their analysis to populations rarely considered in microbiome research. People assigned female at birth are joined by transgender women with neovaginas, whose surgically constructed anatomy hosts a neovaginal microbiome that is notably distinct from that of the vagina, yet is rarely studied in its own right. Hormone replacement therapy, testosterone-dominant physiology and oestrogen-dominant physiology each produce different microbial milieus, yet clinical guidance seldom addresses these variations. Women who have sex with women constitute another understudied group within STI research, despite participating in sexual networks where infections circulate. The cumulative effect of these omissions, the review argues, is a medical landscape in which treatments are designed, tested and approved on the basis of evidence that may not apply to the very patients receiving them.
The technical framework underpinning the argument draws on classical microbial ecology. The vaginal microbiome is treated as an ecological niche, a micro-ecology in which environmental conditions, microbial co-inhabitants and host physiology interact continuously. Oestrogen-dominant VMBs, for example, tend to favour glycogen deposition in the vaginal epithelium, which in turn supports Lactobacillus growth and acidification. Disturbances to this equilibrium, whether through antibiotics, hormonal shifts or sexual exposure, can trigger transitions between community states, some of which are associated with bacterial vaginosis, vulvovaginal candidiasis, urinary tract infections and heightened STI susceptibility. Each transition reshapes the landscape of gene exchange and pathogen survival within the niche.
The review does not claim to have demonstrated that the vaginal microbiome is driving AMR-STI emergence. Rather, it assembles converging lines of evidence and identifies where the knowledge gaps lie. How does VMB composition affect the efficiency of horizontal gene transfer involving STI pathogens in vivo? Do biofilm-forming anaerobes serve as reservoirs of resistance genes that can be mobilized into pathogens? How do prophylactic antibiotic programs aimed at one population influence resistance dynamics in the untreated partners of that population? None of these questions, the authors argue, can be answered without research that simultaneously attends to microbial ecology and social context, because the two are intertwined at every level.
The authors call for a research agenda that centres the populations long excluded from sexual health science. They urge study of how intersecting social, sexual, behavioural and biological factors shape STI risk within the vaginal microbiome, how these factors operate for sexuality and gender diverse individuals, and ultimately how the combination influences the trajectory of AMR-STI evolution. Given the global spread of resistant gonorrhoea and the growing spectre of untreatable infections, the stakes of such research extend well beyond any single country or community.
In framing the vagina as both a microbial ecosystem and a socially embedded one, the review offers a perspective that is likely to resonate far beyond microbiology. Public health interventions that ignore ecology risk selecting for the very threats they aim to prevent, and interventions that ignore social reality risk leaving the most vulnerable populations unprotected and unstudied. The vaginal microbiome, the authors suggest, sits precisely at the intersection of these failures, and understanding it may prove essential to keeping drug-resistant STIs in check. Until the microbial and the social are studied together, the conditions favouring AMR-STI emergence may quietly persist, invisible in laboratory data and policy documents alike, thriving in the gap between how infections are treated and how people actually live.
Cite Scienmag News
Morgan Morrow. (September 7, 2026). Vaginal microbiome ecology shapes antimicrobial resistance and STI acquisition risk. Scienmag. https://scienmag.com/vaginal-microbiome-ecology-shapes-antimicrobial-resistance-and-sti-acquisition-risk/
Morgan Morrow. "Vaginal microbiome ecology shapes antimicrobial resistance and STI acquisition risk." Scienmag, 7 September 2026, https://scienmag.com/vaginal-microbiome-ecology-shapes-antimicrobial-resistance-and-sti-acquisition-risk/. Accessed 7 September 2026.
Morgan Morrow. "Vaginal microbiome ecology shapes antimicrobial resistance and STI acquisition risk." Scienmag. September 7, 2026. https://scienmag.com/vaginal-microbiome-ecology-shapes-antimicrobial-resistance-and-sti-acquisition-risk/

